Cochrane · systematic review · CD013210
Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta‐analysis
Iheozor‐Ejiofor, Z, Gordon, M, Clegg, A, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
27
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 10%Very low 18 · 60%Low 8 · 26.7%Moderate 1 · 3.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Estimates of effects, credible intervals, and certainty of the evidence for maintenance of surgically induced remission in Crohn's disease
Population: surgically induced remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Placebo Comparator | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Rank 8 (6 to 10) | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Rank 5 (3 to 7) | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Rank 4 (2 to 7) | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision |
Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease: BENEFITS
Population: surgically induced remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adalimumab (2 RCTs; 26 participants) | HR 0.11 [0.02, 0.33] | 2 studies · 26 participants | Low Downgraded: risk of bias, imprecision |
Infliximab (2 RCTs; 21 participants) | HR 0.36 [0.02, 1.74] | 2 studies · 21 participants | Very low Downgraded: risk of bias, imprecision |
Budesonide (1 RCT; 43 participants) | HR 0.66 [0.27, 1.34] | 1 study · 43 participants | Low Downgraded: imprecision |
5‐ASA (9 RCTs; 542 participants) | HR 0.69 [0.53, 0.87] | 5 studies · 9 participants | Moderate Downgraded: risk of bias |
Purine analogues (6 RCTs; 316 participants) | HR 0.75 [0.55, 1] | 6 studies · 316 participants | Low Downgraded: risk of bias, inconsistency |
Sulfasalazine (2 RCTs; 143 participants) | HR 0.89 [0.55, 1.3] | 2 studies · 143 participants | Very low Downgraded: risk of bias, imprecision |
Antibiotics (2 RCTs; 57 participants) | HR 0.98 [0.5, 1.71] | 2 studies · 57 participants | Very low Downgraded: risk of bias, imprecision |
Probiotics (2 RCTs; 105 participants) | HR 1.11 [0.62, 1.88] | 2 studies · 105 participants | Very low Downgraded: risk of bias, imprecision |
Sulfasalazine + prednisolone (1 RCT; 57 participants) | HR 1.37 [0.5, 3.07] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Placebo (16 RCTs; 935 participants) | no estimate extracted | 16 studies · 935 participants | Ungraded |
Estimates of effects, credible intervals, and certainty of the evidence for the maintenance of surgically induced remission in Crohn's disease: BENEFITS
Population: surgically induced remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adalimumab (3 RCTs; 37 participants) | HR 0.1 [0.01, 0.32] | 3 studies · 37 participants | Low Downgraded: risk of bias, imprecision |
Infliximab (2 RCTs; 21 participants) | HR 0.24 [0.01, 1.2] | 2 studies · 21 participants | Low Downgraded: risk of bias, imprecision |
Antibiotics (2 RCTs; 57 participants) | HR 0.8 [0.33, 1.65] | 2 studies · 57 participants | Very low Downgraded: risk of bias, imprecision |
Purine analogues (4 RCTs; 164 participants) | HR 0.85 [0.33, 1.61] | 4 studies · 164 participants | Very low Downgraded: risk of bias, imprecision |
Probiotics (3 RCTs; 108 participants) | HR 1.2 [0.62, 2.19] | 3 studies · 108 participants | Very low Downgraded: risk of bias, imprecision |
5‐ASA (3 RCTs; 237 participants) | HR 1.22 [0.61, 2.18] | 3 studies · 5 participants | Very low Downgraded: risk of bias, imprecision |
Placebo (8 RCTs; 507 participants) | no estimate extracted | 8 studies · 507 participants | Ungraded |
Interventions for the maintenance of surgically induced remission in Crohn's disease: HARMS
Population: surgically induced remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sulfasalazine (1 RCT; 32 participants) | HR 1.96 | 1 study · 32 participants | Very low Downgraded: risk of bias, imprecision |
Infliximab (1 RCT; 11 participants) | HR 6.37 | 1 study · 11 participants | Very low Downgraded: risk of bias, imprecision |
5‐ASA (8 RCTs; 371 participants) | HR 1.19 [0.39, 3.14] | 5 studies · 8 participants | Very low Downgraded: risk of bias, imprecision |
Budesonide (2 RCTs; 106 participants) | HR 1.64 [0.17, 6.19] | 2 studies · 106 participants | Very low Downgraded: risk of bias, imprecision |
Probiotic (1 RCT; 58 participants) | HR 2.44 [0.13, 9] | 1 study · 58 participants | Very low Downgraded: risk of bias, imprecision |
Adalimumab (1 RCT; 16 participants) | HR 11.74 [0.12, 55.06] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Purine analogues (7 RCTs; 315 participants) | HR 2.51 [0.79, 7.35] | 7 studies · 315 participants | Very low Downgraded: risk of bias, imprecision |
Antibiotics (1 RCT; 16 participants) | HR 53.92 [0.43, 259.8] | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Placebo (10 RCTs; 531 participants) | no estimate extracted | 10 studies · 531 participants | Ungraded |